These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 31138931)
1. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Mikhail FM; Biegel JA; Cooley LD; Dubuc AM; Hirsch B; Horner VL; Newman S; Shao L; Wolff DJ; Raca G Genet Med; 2019 Sep; 21(9):1903-1916. PubMed ID: 31138931 [TBL] [Abstract][Full Text] [Related]
2. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Xu X; Bryke C; Sukhanova M; Huxley E; Dash DP; Dixon-Mciver A; Fang M; Griepp PT; Hodge JC; Iqbal A; Jeffries S; Kanagal-Shamanna R; Quintero-Rivera F; Shetty S; Slovak ML; Yenamandra A; Lennon PA; Raca G Cancer Genet; 2018 Dec; 228-229():218-235. PubMed ID: 30344013 [TBL] [Abstract][Full Text] [Related]
3. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Chun K; Wenger GD; Chaubey A; Dash DP; Kanagal-Shamanna R; Kantarci S; Kolhe R; Van Dyke DL; Wang L; Wolff DJ; Miron PM Cancer Genet; 2018 Dec; 228-229():236-250. PubMed ID: 30554732 [TBL] [Abstract][Full Text] [Related]
4. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Riggs ER; Andersen EF; Cherry AM; Kantarci S; Kearney H; Patel A; Raca G; Ritter DI; South ST; Thorland EC; Pineda-Alvarez D; Aradhya S; Martin CL Genet Med; 2020 Feb; 22(2):245-257. PubMed ID: 31690835 [TBL] [Abstract][Full Text] [Related]
5. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Kanagal-Shamanna R; Hodge JC; Tucker T; Shetty S; Yenamandra A; Dixon-McIver A; Bryke C; Huxley E; Lennon PA; Raca G; Xu X; Jeffries S; Quintero-Rivera F; Greipp PT; Slovak ML; Iqbal MA; Fang M Cancer Genet; 2018 Dec; 228-229():197-217. PubMed ID: 30377088 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma. Marescalco MS; Capizzi C; Condorelli DF; Barresi V J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501 [TBL] [Abstract][Full Text] [Related]
7. [Standards for the interpretation of constitutional copy number gain: Recommendation from the American College of Medical Genetics and Genomics (ACMG) and Clinical Genome Resource (ClinGen)]. Chen X; Shangguan S; Xie H; Liu H; Liu W; An Y; Shen Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 Jan; 39(1):1-10. PubMed ID: 34964957 [TBL] [Abstract][Full Text] [Related]
8. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. Li MM; Datto M; Duncavage EJ; Kulkarni S; Lindeman NI; Roy S; Tsimberidou AM; Vnencak-Jones CL; Wolff DJ; Younes A; Nikiforova MN J Mol Diagn; 2017 Jan; 19(1):4-23. PubMed ID: 27993330 [TBL] [Abstract][Full Text] [Related]
9. Adapting ACMG/AMP sequence variant classification guidelines for single-gene copy number variants. Brandt T; Sack LM; Arjona D; Tan D; Mei H; Cui H; Gao H; Bean LJH; Ankala A; Del Gaudio D; Knight Johnson A; Vincent LM; Reavey C; Lai A; Richard G; Meck JM Genet Med; 2020 Feb; 22(2):336-344. PubMed ID: 31534211 [TBL] [Abstract][Full Text] [Related]
10. Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. Liu YJ; Houldsworth J; Emmadi R; Dyer L; Wolff DJ Cancer Genet; 2020 Jun; 244():40-54. PubMed ID: 32434132 [TBL] [Abstract][Full Text] [Related]
11. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Shao L; Akkari Y; Cooley LD; Miller DT; Seifert BA; Wolff DJ; Mikhail FM; Genet Med; 2021 Oct; 23(10):1818-1829. PubMed ID: 34131312 [TBL] [Abstract][Full Text] [Related]
12. Copy number alterations involving 59 ACMG-recommended secondary findings genes. Yatsenko SA; Aarabi M; Hu J; Surti U; Ortiz D; Madan-Khetarpal S; Saller DN; Bellissimo D; Rajkovic A Clin Genet; 2020 Dec; 98(6):577-588. PubMed ID: 33009833 [TBL] [Abstract][Full Text] [Related]
13. Correspondence on "Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)" by Riggs et al. Spurdle AB; Drackley A; Ing A; Tudini E; Yap KL; Tavtigian SV Genet Med; 2023 Aug; 25(8):100868. PubMed ID: 37261439 [No Abstract] [Full Text] [Related]
14. Genome-Wide Copy Number Variation Detection Using NGS: Data Analysis and Interpretation. Shen W; Szankasi P; Durtschi J; Kelley TW; Xu X Methods Mol Biol; 2019; 1908():113-124. PubMed ID: 30649724 [TBL] [Abstract][Full Text] [Related]
15. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Amendola LM; Jarvik GP; Leo MC; McLaughlin HM; Akkari Y; Amaral MD; Berg JS; Biswas S; Bowling KM; Conlin LK; Cooper GM; Dorschner MO; Dulik MC; Ghazani AA; Ghosh R; Green RC; Hart R; Horton C; Johnston JJ; Lebo MS; Milosavljevic A; Ou J; Pak CM; Patel RY; Punj S; Richards CS; Salama J; Strande NT; Yang Y; Plon SE; Biesecker LG; Rehm HL Am J Hum Genet; 2016 Jun; 98(6):1067-1076. PubMed ID: 27181684 [TBL] [Abstract][Full Text] [Related]
16. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439 [TBL] [Abstract][Full Text] [Related]
17. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Richards S; Aziz N; Bale S; Bick D; Das S; Gastier-Foster J; Grody WW; Hegde M; Lyon E; Spector E; Voelkerding K; Rehm HL; Genet Med; 2015 May; 17(5):405-24. PubMed ID: 25741868 [TBL] [Abstract][Full Text] [Related]
18. Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. Hu N; Clifford RJ; Yang HH; Wang C; Goldstein AM; Ding T; Taylor PR; Lee MP BMC Genomics; 2010 Oct; 11():576. PubMed ID: 20955586 [TBL] [Abstract][Full Text] [Related]
19. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M; Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007 [TBL] [Abstract][Full Text] [Related]
20. Section E6.1-6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes. Akkari Y; Baughn LB; Kim A; Karaca E; Raca G; Shao L; Mikhail FM; Genet Med; 2024 Apr; 26(4):101054. PubMed ID: 38349293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]